Urgent

Visceral leishmaniasis (kala-azar; Leishmania donovani; incl. PKDL)

Chronic fever + massive splenomegaly + pancytopenia from Bihar/endemic area; liposomal amphotericin B · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Systemic protozoal infection by Leishmania (L. donovani in India/East Africa), transmitted by sandflies. Classic: prolonged (weeks-months) fever, marked splenomegaly (often hepatomegaly), weight loss, pancytopenia and hyperglobulinaemia; fatal untreated. Endemic in Bihar and neighbouring Indian states. Single-dose liposomal amphotericin B is the mainstay in the Indian subcontinent; consider HIV coinfection.

Red flags

  • Severe pancytopenia with bleeding or neutropenic sepsis
  • Haemophagocytic lymphohistiocytosis (HLH) picture
  • Jaundice, massive splenomegaly with hypersplenism
  • HIV coinfection / immunosuppression (poor response, relapse)
  • PKDL (hypopigmented macules/nodules after treatment) - infectious reservoir

Assessment

Differential diagnosis

  • Malaria, enteric fever, miliary TB
  • Haematological malignancy (lymphoma, leukaemia), myelofibrosis
  • Chronic brucellosis, disseminated histoplasmosis
  • Tropical splenomegaly / portal hypertension
  • HIV with opportunistic infection

Investigations

  • rK39 rapid immunochromatographic test (high sensitivity in Indian VL) - first-line serology
  • Demonstration of amastigotes (Leishman-Donovan bodies) on splenic/bone-marrow aspirate (splenic highest yield but risk) or culture/PCR
  • FBC (pancytopenia), high ESR, raised globulins/reversed A:G ratio, LFTs
  • HIV test (coinfection alters management and relapse risk)
  • Baseline renal/electrolytes (amphotericin), pregnancy test

Management

  • Confirm diagnosis (rK39 + clinical in endemic area; tissue if atypical/relapse/immunocompromised)
  • Assess and correct cytopenias, nutrition, intercurrent infection
  • Treat with liposomal amphotericin B (national programme regimen in India)
  • Monitor renal function, electrolytes (K/Mg) and infusion reactions during amphotericin
  • Test for and manage HIV; immunocompromised need longer regimens and secondary prophylaxis
  • Follow up for relapse and post-kala-azar dermal leishmaniasis (PKDL - a transmission reservoir; report for treatment)

Drugs & doses

Liposomal amphotericin B (AmBisome) single dose 10 mg/kg IV (Indian subcontinent immunocompetent; NEJM 2010 ~95% cure) - national kala-azar elimination regimen
Alternative multi-dose liposomal amphotericin B 3-5 mg/kg/day to total ~15-21 mg/kg (e.g. East Africa/HIV) [verify local]
Miltefosine 2.5 mg/kg/day PO (max 150 mg/day) 28 days - oral option; TERATOGENIC, contraception required; rising relapse
Amphotericin B deoxycholate 1 mg/kg IV alternate days to total 15-20 mg/kg (cheaper, nephrotoxic) where liposomal unavailable
Paromomycin 11 mg/kg/day IM 21 days (combination regimens used in elimination programmes)
HIV coinfection: liposomal amphotericin B higher total dose +/- miltefosine, then secondary prophylaxis [verify local]

Disposition

Admit for diagnosis confirmation, parenteral therapy and supportive care; monitor renal function and counts. ID/haematology input; link to national kala-azar programme. Follow-up for relapse and PKDL surveillance.

Complications & pitfalls

  • Secondary bacterial infection, sepsis (leading cause of death)
  • Severe anaemia, bleeding from thrombocytopenia
  • HLH / secondary haemophagocytosis
  • Relapse (especially HIV)
  • Post-kala-azar dermal leishmaniasis (PKDL)

Exam pearls

  • Chronic fever + massive splenomegaly + pancytopenia from Bihar/endemic belt = think kala-azar; rK39 is a reliable bedside test in India
  • Single-dose liposomal amphotericin B 10 mg/kg is the backbone of India's kala-azar elimination programme (NEJM 2010)
  • Death is usually from secondary infection/bleeding - treat intercurrent infection and support counts
  • Miltefosine is oral but teratogenic and relapse rates are rising - ensure contraception and follow-up
  • Always test for HIV; coinfection needs intensified therapy and secondary prophylaxis. Report PKDL - it sustains transmission

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.